This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by JOHNSON, R. L. Articles by SCHNAPER, H. W. Search for Related Content PubMed PubMed Citation Articles by JOHNSON, R. L. Articles by SCHNAPER, H. W. Pubmed/NCBI databases Medline Plus Health Information High Blood Pressure

(Circulation. 1952;5:833.)
© 1952 American Heart Association, Inc.

---

Clinical Evaluation of 1-Hydrazinophthalazin (C-5968) in Hypertension

With Special Reference to Alternating Treatment With Hexamethonium

ROBERT L. JOHNSON ¹; EDWARD D. FREIS M.D.¹; HAROLD W. SCHNAPER M.D.¹

¹ From The Cardiovascular Research Laboratory, Georgetown University Hospital; the Department of Medicine, Georgetown University School of Medicine and the Veterans Administration Hospital, Washington, D. C.

Single oral doses of 1-hydrazinophthalazine frequently lowered blood pressure particularly diastolic pressure in hypertensive patients. Prolonged therapy was less successful, apparently as a result of development of tolerance or side effects. The best long-term results were obtained when l-hydrazinophthalazine was alternated with hexamethonium.

This article has been cited by other articles:

				M. J. Kert, S. Rosenfeld, R. H. Mailman, J. P. Westergart, H. G. Carleton, and E. Hiscock Clinical Evaluation of Hydralazine (Apresoline) Alone and in Combination with Veriloid in the Treatment of Hypertension Angiology, August 1, 1954; 5(4): 318 - 328. [PDF]

				R. S. SCHAAF CARDIOVASCULAR DISEASES: A Review of Some Significant Publications (July 1949-June 1952) Arch Intern Med, March 1, 1954; 93(3): 407 - 463. [Abstract] [PDF]